Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$80.78

0.07 (0.09%)

, ICPT

Intercept

$95.04

-9.71 (-9.27%)

04:55
04/14/19
04/14
04:55
04/14/19
04:55

European Association for the Study of the Liver to hold a meeting

EASL International Liver Congress 2019 will be held in Vienna, Austria on April 10-14.

ABBV

AbbVie

$80.78

0.07 (0.09%)

ICPT

Intercept

$95.04

-9.71 (-9.27%)

VRTX

Vertex

$182.69

-2.4 (-1.30%)

GILD

Gilead

$65.27

-1.04 (-1.57%)

AGN

Allergan

$144.94

-0.08 (-0.06%)

GNFT

Genfit

$24.84

-0.02 (-0.08%)

ALNY

Alnylam

$89.78

1.68 (1.91%)

APEN

Apollo Endosurgery

$3.43

-0.025 (-0.72%)

BMY

Bristol-Myers

$45.58

-0.52 (-1.13%)

CBAY

CymaBay

$12.50

-0.6 (-4.58%)

CTSO

CytoSorbents

$7.16

-0.28 (-3.76%)

EIGR

Eiger BioPharmaceuticals

$14.25

-0.04 (-0.28%)

ENTA

Enanta

$92.32

0.42 (0.46%)

NDRA

ENDRA Life Sciences

$1.51

(0.00%)

IPSEY

Ipsen

$0.00

(0.00%)

MYRG

MYR Group

$36.36

-0.14 (-0.38%)

NVS

Novartis

$80.26

-1.615 (-1.97%)

NVO

Novo Nordisk

$50.21

-0.74 (-1.45%)

OSUR

OraSure

$10.12

-0.12 (-1.17%)

SIEGY

Siemens

$0.00

(0.00%)

JNJ

Johnson & Johnson

$136.00

0.72 (0.53%)

SBPH

Spring Bank Pharmaceuticals

$9.54

-0.29 (-2.95%)

  • 16

    Apr

  • 17

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 03

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 18

    May

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 28

    May

  • 29

    May

  • 05

    Jun

  • 06

    Aug

  • 13

    Nov

ABBV AbbVie
$80.78

0.07 (0.09%)

04/11/19
EVER
04/11/19
INITIATION
Target $30
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.
03/25/19
ARGS
03/25/19
DOWNGRADE
ARGS
Hold
AbbVie downgraded to Hold from Buy at Argus
03/25/19
03/25/19
DOWNGRADE

Hold
AbbVie downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded AbbVie to Hold, saying its flagship program Humira "no longer looks invulnerable to competition from biosimilars in Europe and other overseas markets." The analyst notes that Humira is also faced with "indirect competition from newer drugs that have an alternative mechanism of action" compared to Humira's anti-TNF class. Toung further cites AbbVie's clinical setback with Venclexta, which highlights the risks for the company as it develops a pipeline aimed to offset the expected decline in Humira sales.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
ICPT Intercept
$95.04

-9.71 (-9.27%)

04/11/19
JEFF
04/11/19
NO CHANGE
JEFF
Buy
Jefferies doesn't see any major issues with Intercept data
Jefferies analyst Michael Yee does not see any major issues with the data this morning reported by Intercept Pharmaceuticals. The analyst attributes the corresponding stock selloff to a trading dynamic given the 20% move off the bottom over the last few week. The market now anticipates a window of waiting for filing and approval, Yee tells investors in a research note. He believes further analysis of the Phase III Regenerate study shows an even greater efficacy profile and "slowing" progressors for obeticholic acid. The further efficacy clearly suggest a "higher rate of fibrosis improvement" than the initial 23% versus 12% that some key opinion leaders cite, but also that the drug is "slowing" the disease by preventing many more patients from fibrosis progression which is important to prevent eventual cirrhosis, Yee contends. He has a Buy rating on shares of Intercept.
04/12/19
WELS
04/12/19
NO CHANGE
Target $104
WELS
Market Perform
Intercept fairly valued following yesterday's data, says Wells Fargo
Wells Fargo analyst Jim Birchenough views Intercept Pharmaceuticals as fairly valued following his review of the secondary endpoint per protocol analysis from the Phase 3 Regenerate study of obeticholic acid in non-alcoholic steatohepatitis. The analyst modestly raised his price target for the stock to $104 and keeps a Market Perform rating on the name. While the per protocol analysis should strengthen the conviction in obeticholic acid benefit in reversing histologic features of NASH in patients adhering to longer term treatment, the intent to treat analysis provides a better integrated perspective on expected real-world benefit, accounting for missed doses, non-adherence, drug discontinuations and other contributors to the "significant" number of patients in Regenerate that didn't meet per protocol requirements, Birchenough tells investors in a research note. The analyst increased the probability of approval for obeticholic acid in NASH following yesterday's data, but leaves his estimates unchanged as he believes that "breadth of use may be limited by potential liver biopsy requirements, high rate of pruritus, and potential drug discontinuation rates and that product labeling and reimbursement considerations will be key."
04/12/19
RBCM
04/12/19
NO CHANGE
RBCM
Outperform
Intercept's OCA risk-benefit profile still looks solid, says RBC Capital
RBC Capital analyst Brian Abrahams kept his Outperform rating on Intercept (ICPT) after its Regenerate data in the 25mg obeticholic acid, or OCA, study and the subsequent 13% decline in its stock price. The analyst believes that the sell-off was in part a "sell the news" event and also may have been driven by the separately announced 20% sales force layoff at Gilead (GILD), which had been viewed as a potential buyer of NASH assets. Abrahams maintains his view on OCA's benefit/risk profile as "solid", adding that while fundamental concerns around the launch and necessary capital are likely to remain, he expects its "likely approval and broad long-term market opportunity" to become "better appreciated in the medium-term."
04/11/19
ROTH
04/11/19
NO CHANGE
Target $192
ROTH
Buy
Roth Capital doesn't just like the new Intercept data, it loves it
"We don't just like the new data, we love it," Roth Capital analyst Yasmeen Rahimi writes in a research note following this morning's data release from Intercept Pharmaceuticals Three-fold more patients in the 25mg obeticholic acid group achieved fibrosis improvements equal to or greater than two stages versus placebo, Rahimi points out. Some payers may grant higher pricing for drugs with strong potency, and further, this "one-line" efficacy data is going to drive adoption, contends the analyst. With that said, Rahim also found "more color for the angry bears." Pruritus incidence across groups highest in first three months and decreased afterwards, she notes. Further, LDL-C peaked at week four of 22.6mg/dL but approached baseline at month 18. The analyst, however, calls this "no big deal." She keeps a Buy rating on Intercept with a $192 price target. The stock in morning trading is down 12%, or $14.42, to $106.26.
VRTX Vertex
$182.69

-2.4 (-1.30%)

04/11/19
EVER
04/11/19
INITIATION
Target $183
EVER
In Line
Vertex initiated with an In Line at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Vertex with an In-Line rating and a price target of $183. The analyst says the company has "great science, execution, and management", but its multiple is the highest relative to its peers and appears to be "priced to perfection". Mehrotra adds that the debate around EU pricing will intensify, becoming a "bigger and longer headwind".
03/26/19
HCWC
03/26/19
NO CHANGE
Target $15
HCWC
Buy
Proteostasis regiments warrant further investigation, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein says it was his hope that the Proteostasis (PTI) compounds would generate a 10 ppFEV1 improvement and provide either a legitimate competitor for Vertex (VRTX) or identification of molecules that could serve as possible add-ons to other shelved or early development modulators. Factually, none of the dose cohorts measured at either seven-day or 14-days after treatment generated a 10 ppFEV1 improvement, Fein tells investors in a research note. However, due to the complete lack of any competition to the Vertex "strangle-hold" on the cystic fibrosis landscape as well as the "apparent if not overwhelming desire," at least outside of the U.S., for a second option, the Proteostasis regiments warrant further investigation, says the analyst. He believes yesterday's data may provide an opportunity in more severe cystic fibrosis patients. Fein keeps a Buy rating on Proteostasis with a $15 price target. The stock closed yesterday down 68%, or $2.76, to $1.31.
03/26/19
03/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Strong Buy from Market Perform at Raymond James , to Hold from Sell at Loop Capital, and to Sector Weight from Underweight at KeyBanc. 2. BB&T (BBT) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying after meeting with CEO of SunTrust (STI), he remains positive on the merger and the combined stock. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at William Blair with analyst Y. Katherine Xu citing expectations that the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. 4. Allegiant Travel (ALGT) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio citing her meetings with its management last week. 5. TransAlta (TAC) upgraded to Buy from Hold at TD Securities with analyst John Mould saying Brookfield Renewable Partners (BEP) $750M investment in TransAlta improves the company's financial flexibility, accelerates its ability to return capital to shareholders and advance the coal-to-gas conversion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$65.27

-1.04 (-1.57%)

03/17/19
PIPR
03/17/19
NO CHANGE
Target $75
PIPR
Neutral
Gilead HIV drugs' price increase 30% lower than prior years, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren notes that as expected, effective March 16th, Gilead raised list prices of the company's top 6 selling HIV antiviral drugs by 4.9% which includes Atripla, Biktarvy, Descovy, Genvoya, Odefsey, and Truvada. Notably, the price increases were roughly 30% lower than what has been observed in prior years and likely reflects the recent increasing pressure on drug pricing, he contends. The analyst also notes that these increases are well below the high single digit year over year price increases that have been observed with other companies, which Gilead can afford due to strong volume growth of its next generation TAF-based regimens. Van Buren reiterates a Neutral rating and $75 price target on the shares.
04/10/19
UBSW
04/10/19
UPGRADE
Target $77
UBSW
Buy
Gilead upgraded to Buy from Neutral at UBS
UBS analyst Carter Gould upgraded Gilead Sciences to Buy from Neutral and raised his price target for the shares to $77 from $75. Following the failure of selonsertib in nonalcoholic steatohepatitis, Gilead announced "two important clinical wins" in the positive Descovy PrEP data and filgotinib Finch1/3 data, Gould tells investors in a research note. These unlock two $2B-plus revenue opportunities and go "far to de-risk" the company's growth in 2021 and beyond, contends the analyst. Further, while the analyst expects a Q1 earnings miss, he believes 2019 estimates will move higher as NASH precommercialization spend likely comes out of guidance.
03/15/19
03/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simmons First National (SFNC) initiated with a Buy at DA Davidson. 2. Amgen (AMGN) and Gilead (GILD) initiated with an Outperform at BMO Capital. 3. Rocket Pharmaceuticals (RCKT) initiated with a Buy at BofA/Merrill. 4. Urovant Sciences (UROV) initiated with a Buy at SunTrust. 5. Spectrum (SPPI) assumed with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AGN Allergan
$144.94

-0.08 (-0.06%)

04/11/19
EVER
04/11/19
INITIATION
Target $34
EVER
Outperform
Editas Medicine initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Editas Medicine (EDIT) with an Outperform rating and a price targets of $34. The analyst cites the company's "strong clinical positioning of lead program EDIT-101", saying that if its efficacy is demonstrated in LCA-10 and proven durable, it will likely have "significant uptake over Sepofarsen, which requires chronic dosing." Mehrotra adds that Editas Medicine's partnership with Allergan (AGN) "adds reinforcement".
04/02/19
STFL
04/02/19
NO CHANGE
Target $175
STFL
Hold
Stifel says abicipar improvement not enough to make Allergan drug competitive
After Allergan reported data from its 28-week open-label safety study, MAPLE, to evaluate the safety of abicipar produced via a modified manufacturing process, Stifel analyst Annabel Samimy noted that overall inflammation was reduced to 8.9% and severe inflammation to 1.6%. However, her talks with key opinion leading physicians lead her to conclude that the MAPLE inflammation rates are still too high compared to other "extremely safe" and effective options on the market today. Increasing competition on efficacy, dosing length, and price, as well as the still-high inflammation rates, continue to limit any meaningful commercial opportunity for abicipar, said Samimy, who keeps a Hold rating on Allergan shares.
03/20/19
PIPR
03/20/19
NO CHANGE
Target $161
PIPR
Neutral
Piper Jaffray questions value creation of potential Allergan break up
There is some thought among investors that a separation of Allergan (AGN) into its global medical aesthetics business and its pharma business should unlock significant value, Piper Jaffray analyst David Amsellem tells investors in a research note titled "A Break Up Is By No Means A Panacea; Staying Cautious." The analyst's questions this thinking, saying this course of action "cannot paper over the challenges" facing both businesses. His sum-of-the-parts analyses suggest that a break-up "would confer only modest value creation." And even that may not be sustainable as competitive challenges surrounding Botox and losses of exclusivities beyond Restasis come into focus, contends Amsellem. "Simply put, a separation in and of itself is not the transformative change we would be looking for," says the analyst. He reiterates a Neutral rating on Allergan with a $161 price target.
03/22/19
ADAM
03/22/19
NO CHANGE
ADAM
Buy
Breast implant panel documents in-line with expectations, says Canaccord
Canaccord analyst Kyle Rose maintains his Buy rating on Sientra (SIEN) following the release of briefing documents ahead of next week's FDA panel meeting to review a range of topics related to the long-term benefits and risks of breast implants, stating that the documents appear to be in-line with expectations and do not appear to raise any materially new or concerning questions or data. However, given the warning letters sent this week to Sientra and J&J's (JNJ) Mentor unit, Rose said he expects the FDA to "take a strong tone" during the panel about the responsibility to support the collection and analysis of relevant safety and efficacy clinical data. Other makers of breast implants include Allergan (AGN) and Establishment Labs (ESTA).
GNFT Genfit
$24.84

-0.02 (-0.08%)

ALNY Alnylam
$89.78

1.68 (1.91%)

04/08/19
PIPR
04/08/19
NO CHANGE
Target $142
PIPR
Overweight
Alnylam alliance with Regeneron a 'clear positive,' says Piper Jaffray
Alnylam Pharmaceuticals (ALNY) today concluded its 2014 RNAi discovery collaboration with Sanofi (SNY) and announced a new five-year RNAi drug discovery alliance with Regeneron Pharmaceuticals (REGN), Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Alnylam will receive $400M in cash and Regeneron will make a $400M equity investment at $90 per Alnylam share, bringing its estimated pro forma cash to $2.3B, adds the analyst. He believes the alliance is a "clear positive for Alnylam "dramatically expanding" its RNAi drug discovery capabilities and strengthening its balance sheet to advance its own orphan disease programs. Tenthoff reiterates an Overweight rating on Alnylam with a $142 price target. The stock in early trading is down 3%, or $2.95, to $89.94.
04/09/19
BMOC
04/09/19
NO CHANGE
Target $119
BMOC
Outperform
Alnylam price target raised to $119 from $106 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam (ALNY) to $119 and kept his Outperform rating after its announced Regeneron (REGN) partnership on ocular / CNS diseases and liver-related diseases. The analyst expects the collaboration to result in favorable economics that also gives Alnylam an opportunity to co-promote its CNS program, but warns that some pressure on the stock is possible since the equity investment component by Regeneron at $90 per share was $3 below Friday's close.
04/09/19
LEER
04/09/19
NO CHANGE
Target $70
LEER
Market Perform
Alnylam price target raised to $70 from $65 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Alnylam (ALNY) to $70 from $65 after the company announced a collaboration with Regeneron (REGN) to develop and commercialize RNAi therapeutics with a focus on CNS and ocular indications, along with liver-directed NASH therapies and cemdisiran in combination with pozelimab. The analyst believes the terms of the deal, which includes a $400M upfront payment and a $400M equity investment in Alnylam at $90/share, are favorable for Alnylam. Foroohar reiterates a Market Perform rating on Alnylam's shares.
04/11/19
EVER
04/11/19
INITIATION
Target $120
EVER
Outperform
Alnylam initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Alnylam with an Outperform rating and a price targets of $120, citing the "strength of its Onpattro franchise and high modality modularity." The analyst contends that the company's modular platform enables its "sustainable growth opportunities", points to its Lumasiran Phase 3 results being a "resounding win", and also notes that all of the company's pipeline segments are advancing.
APEN Apollo Endosurgery
$3.43

-0.025 (-0.72%)

03/18/19
PIPR
03/18/19
NO CHANGE
Target $5.5
PIPR
Overweight
Piper says Apollo's OverStitch growth more important than balloon sales declines
Piper Jaffray analyst JP McKim noted that Apollo Endosurgery reported Q4 sales and gave 2019 guidance that were both relatively in-line with estimates, but he believes the fact that OverStitch sales outperformed expectations is more important than the decline in balloon sales. While the early feedback from the alpha launch was positive, McKim believes Apollo will need to show execution on SX sales before seeing its multiple expand. He keeps an Overweight rating and $5.50 price target on Apollo Endosurgery.
01/02/19
NORL
01/02/19
UPGRADE
Target $3
NORL
Market Perform
Apollo Endosurgery upgraded to Market Perform from Underperform at Northland
Northland analyst Suraj Kalia upgraded Apollo Endosurgery to Market Perform and maintained a $3 price target citing valuation.
12/18/18
CHLM
12/18/18
NO CHANGE
CHLM
Craig-Hallum says Apollo's divestiture makes it more attractive takever target
Craig-Hallum analyst Matt Hewitt reiterated a Buy rating and $11 price target on Apollo Endosurgery after the company announced the divestiture of its Surgical segment to ReShape Lifesciences, which brings in $10M immediately along with $7M more in the coming years. Hewitt views the sale as a positive, as the segment had been set to decline by 33% in FY18. The analyst added that now that Apollo is strictly an endo-bariatric company, he views it as "significantly more attractive to potential acquirers."
12/18/18
PIPR
12/18/18
NO CHANGE
Target $5.5
PIPR
Overweight
Apollo Endosurgery target lowered to $5.50 from $7 at Piper Jaffray
Piper Jaffray analyst JP McKim says this morning's sale of its surgical business to ReShape provides Apollo Endosurgery management a "great" opportunity to right-size the company and focus on higher growth, unique assets such as OverStitch SX. Despite the favorable view of the deal, the analyst lowered his price target for the shares to $5.50 from $7.00 based on a reduced 2019 revenue estimate and a slightly reduced target multiple. Management will need to show execution on SX sales before getting the multiple expansion benefit, McKim tells investors in a research note. He keeps an Overweight rating on Apollo Endosurgery.
BMY Bristol-Myers
$45.58

-0.52 (-1.13%)

04/05/19
CANT
04/05/19
DOWNGRADE
Target $100
CANT
Neutral
Cantor sees Bristol deal closing, downgrades Celgene to Neutral
Cantor Fitzgerald analyst Alethia Young downgraded Celgene (CELG) to Neutral from Overweight with an unchanged price target of $100. The analyst expects the takeover by Bristol-Myers (BMY) to close.
04/01/19
UBSW
04/01/19
DOWNGRADE
Target $102
UBSW
Neutral
Celgene downgraded to Neutral from Buy at UBS
UBS analyst Carter Gould downgraded Celgene (CELG) to Neutral from Buy while raising his price target for the shares to $102 from $94. After ISS and Glass Lewis on Friday recommended that Bristol-Myers Squibb (BMY) shareholders vote in favor of the proposed acquisition, and Starboard dropped its proxy solicitation in opposition, the analyst sees an increasingly high probability that Bristol's acquisition of Celgene will be completed. He sees any lingering risks around antitrust concerns and Revlimid litigation as unlikely to derail the deal.
04/01/19
WBLR
04/01/19
DOWNGRADE
WBLR
Market Perform
Celgene downgraded to Market Perform from Outperform at William Blair
William Blair analyst Andy Hsieh downgraded Celgene (CELG) to Market Perform from Outperform saying the recent proxy recommendations set the course for the takeover by Bristol-Myers Squibb (BMY) winning shareholder approval.
04/02/19
BERN
04/02/19
DOWNGRADE
BERN
Market Perform
Celgene downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Aaron Gal downgraded Celgene (CELG) to Market Perform from Outperform as spread narrows. The analyst notes that the current controversy on Celgene is whether the Bristol-Myers (BMY) acquisition will close. With limited upside, no differentiated views on the main controversy, and ahead of the shareholder vote on April 12th, the analyst is moving to the sidelines.
CBAY CymaBay
$12.50

-0.6 (-4.58%)

02/22/19
LEER
02/22/19
INITIATION
Target $22
LEER
Outperform
CymaBay initiated with an Outperform at SVB Leerink
SVP Leerink analyst Pasha Sarraf initiated CymaBay with an Outperform rating and $22 price target, telling investors in a research note that the company is demonstrating "impressive" efficacy and safety profile in PBC and pre-clinically in NASH. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
03/01/19
PIPR
03/01/19
NO CHANGE
Target $30
PIPR
Overweight
Piper Jaffray loves the setup for CymaBay shares into NASH data
CymaBay's Seladelpar has made "tremendous progress" in primary biliary cholangitis over the past year its competitive positioning continues to improve, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, the analyst believes the drug's nonalcoholic steatohepatitis opportunity is not currently being factored into the existing valuation. The analyst expects to receive topline data from the ongoing Phase IIb trial of seladelpar in NASH next quarter. If successful, it could "multiply" the $750M PBC opportunity in his model, Van Buren says in a research note titled "We Love The Setup Of CBAY Here; Reiterate The Overweight." He keeps a $30 price target on CymaBay shares.
02/20/19
PIPR
02/20/19
NO CHANGE
Target $30
PIPR
Overweight
'Underwhelming' Intercept data hurts CymaBay bear thesis, says Piper Jaffray
One of the major constituents of the CymaBay Therapeutics (CBAY) bear thesis has been that pricing for Intercept Pharmaceuticals' (ICPT) Ocaliva would get cut significantly with success in nonalcoholic steatohepatitis and consequently lower the eventual market opportunity for CymaBay's seladelapar in primary biliary cholangitis, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst, however, believes Intercept's Ocaliva data in NASH yesterday was "underwhelming" as the "fibrosis improvement was mild, no significant effect on NASH was observed, and worrisome safety and tolerability issues remain." Questions regarding the commercial viability of Ocaliva in NASH are now likely to persist, says Van Buren. He now believes Intercept will have to target the most severe patients, "significantly narrowing" the drug's addressable population. This should lead to more stable Ocaliva pricing than many currently assume and keep seladelpar's $750M-plus market opportunity in PBC "largely" intact, contends the analyst. Bottom line is that a major constituent of the CymaBay bear thesis has now been removed, he writes. Van Buren keeps an Overweight rating on the shares with a $30 price target. CymaBay Therapeutics closed yesterday up 34c to $10.29.
02/06/19
02/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nasdaq (NDAQ) initiated with a Buy at Argus. 2. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Leerink. 3. PolyOne (POL) initiated with a Buy at Buckingham. 4. Marathon Petroleum (MPC) initiated with an Outperform at Macquarie. 5. CymaBay (CBAY) initiated with a Neutral at B. Riley FBR.This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CTSO CytoSorbents
$7.16

-0.28 (-3.76%)

EIGR Eiger BioPharmaceuticals
$14.25

-0.04 (-0.28%)

10/18/18
PIPR
10/18/18
NO CHANGE
Target $24
PIPR
Overweight
Eiger positive data opens HDV triple combo opportunity, says Piper Jaffray
Eiger BioPharmaceuticals last night announced positive end-of-treatment data from the Phase II study of InterferonLambda in hepatitis delta virus patients, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Importantly, Interferon-Lambda continued to show improved tolerability versus IFN-alfa, which should enable long-term dosing, the analyst contends. He believes the positive data opens up the opportunity for a hepatitis delta virus triple combo. Tenthoff reiterates an Overweight rating on shares of Eiger with a $24 price target.
12/19/18
BTIG
12/19/18
NO CHANGE
Target $47
BTIG
Buy
Eiger BioPharmaceuticals price target raised to $47 from $44 at BTIG
BTIG analyst Robert Hazlett raised his price target for Eiger BioPharmaceuticals to $47 from $44 after the company announced that FDA granted Lonafarnib Breakthrough Therapy for the treatment of Progeria and progeroid laminopathies. The analyst argues that Breakthrough status adds material regulatory and clinical validation to Lonafarnib's accelerated efforts in Progeria and should enable more rapid FDA review. An NDA filing istargeted for early 2019, he notes. Hazlett now models U.S. approval in Progeria in 2019, a Priority Review Voucher awarded and monetized around yearend 2019, and use in progeriod laminopathies, which modestly lifts NPV estimates. The analyst reiterates a Buy rating on the shares.
01/28/19
BARD
01/28/19
INITIATION
Target $47
BARD
Outperform
Eiger BioPharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar started Eiger BioPharmaceuticals with an Outperform rating and $47 price target. The company's hepatitis delta virus pipeline could transform the disease, with lonafarnib monotherapy in progeria can provide near-term, high EBIT margin revenue, Kumar tells investors in a research note.
01/29/19
01/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dell Technologies (DELL) initiated with an Outperform at Raymond James. 2. MasterCard (MA) and Visa (V) were initiated with a Buy at Jefferies. 3. Eiger BioPharmaceuticals (EIGR) initiated with an Outperform at Baird. 4. Arena Pharmaceuticals (ARNA) assumed with an Overweight at Cantor Fitzgerald. 5. Southern Copper (SCCO) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ENTA Enanta
$92.32

0.42 (0.46%)

12/13/18
12/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) assumed with a Buy at Mizuho. 2. Molson Coors (TAP) and Keurig Dr Pepper (KDP) were initiated with a Buy at UBS, while PepsiCo (PEP) and Constellation Brands (STZ) were initiated with a Neutral, and Monster Beverage (MNST) and Boston Beer (SAM) were initiated with a Sell. 3. SeaSpine (SPNE) initiated with an Outperform at Wells Fargo. 4. XPO Logistics (XPO) initiated with a Buy at SunTrust. 5. Enanta (ENTA) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
BREN
12/13/18
INITIATION
Target $80
BREN
Hold
Enanta initiated with a Hold at Berenberg
Berenberg analyst Patrick Trucchio initiated Enanta with a Hold rating and $80 price target.
08/08/18
08/08/18
DOWNGRADE
Target $100

Perform
Enanta downgraded to Perform on HCV headwinds at Oppenheimer
As previously reported, Oppenheimer analyst Jay Olson downgraded Enanta to Perform from Outperform following quarterly results and in the face of HCV headwinds. The analyst lowered his price target on the shares to $100 from $135.
08/08/18
OPCO
08/08/18
DOWNGRADE
OPCO
Perform
Enanta downgraded to Perform from Outperform at Oppenheimer
NDRA ENDRA Life Sciences
$1.51

(0.00%)

IPSEY Ipsen
$0.00

(0.00%)

10/08/18
JPMS
10/08/18
DOWNGRADE
JPMS
Underweight
Ipsen downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Ipsen to Underweight with a price target of EUR 120. The analyst believes the risk/reward is skewed to the downside with the shares "priced for perfection."
02/19/19
GSCO
02/19/19
UPGRADE
GSCO
Neutral
Ipsen upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Diana Na upgraded Ipsen to Neutral citing valuation. The analyst sees a more balanced risk/reward following the stock's recent underperformance.
02/20/19
02/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/04/19
BARD
03/04/19
DOWNGRADE
Target $27
BARD
Neutral
Baird downgrades Clementia to Neutral on lack of data ahead of deal closing
As reported previously, Baird analyst Madhu Kumar downgraded Clementia Pharmaceuticals (CMTA) to Neutral from Outperform. The analyst cited a likely lack of chronic dosing results pre-deal closure with Ipsen (IPSEY). The timing of the deal vote versus MOVE interim data provides little room for upside, said Kumar, who has a $27 on price target on Clementia Pharmaceuticals shares.
MYRG MYR Group
$36.36

-0.14 (-0.38%)

08/03/18
BARD
08/03/18
DOWNGRADE
BARD
Neutral
MYR Group downgraded to Neutral from Outperform at Baird
NVS Novartis
$80.26

-1.615 (-1.97%)

04/10/19
MZHO
04/10/19
NO CHANGE
Target $41
MZHO
Buy
Alcon spinoff shows Bausch Health is undervalued, says Mizuho
Mizuho analyst Irina Koffler reiterates a Buy rating on Bausch Health Companies (BHC) with a $41 price target following Novartis' (NVS) spinoff of Alcon (ALC). Bausch's smaller B+L segment should trade at a "slight discount" to market leader Alcon, but calculate that the market is currently assigning only a 13 times 2019 enterprise value to EBITA multiple to the B+L business, Koffler tells investors in a research note. This highlights that Bausch Health is undervalued, contends the analyst.
04/10/19
MSCO
04/10/19
INITIATION
Target $65
MSCO
Overweight
Alcon initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lewis initiated Alcon (ALC) with an Overweight rating and $65 price target, stating that he expects its pipeline, sales and capex reinvestment to drive an inflection in revenue growth and margin expansion post the spinoff from Novartis (NVS). Near-term improvement at Alcon hinges on the two key PanOptix and PRECISION1 franchises, Lewis noted.
04/10/19
04/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Reduce from Hold at HSBC with analyst Erwan Rambourg saying the returns from Apple's recent announcements, including the Apple News+ premium news subscription, the Apple Card in partnership with Goldman Sachs (GS), Apple Arcade games as part of the App store and video subscription Apple TV+, could "take some time to extract." 2. AmerisourceBergen (ABC) downgraded to In Line from Outperform at Evercore ISI with analyst Michael Cherry citing group profit questions, lack of clarity with PharMEDium, and a reduction in multiple for peers Cardinal Health (CAH) and McKesson (MCK). 3. Novartis (NVS) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Mark Purcell saying the spinoff of Alcon will put more attention on the generics risk Novartis faces in its pharma business. 4. TerraForm Power (TERP) downgraded to Sell from Neutral at Goldman Sachs with analyst Brian Lee saying that while the company is in the midst of an operational transition that may improve cash flow and dividend flexibility, the upside appears to be priced in. 5. Foot Locker (FL) assumed with a Neutral from Buy at Citi with analyst Paul Lejuez saying while Foot Locker has "tailwinds at its back" in North America with comps inflecting positively in Q4, the company still faces many of the same headwinds as other specialty retailers given its "significant" mall exposure and EBIT pressure from direct-to-consumer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
MSCO
04/10/19
DOWNGRADE
MSCO
Underweight
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Mark Purcell downgraded Novartis (NVS) to Underweight from Equal Weight and lowered his price target for the shares to 80 francs. The spinoff of Alcon will put more attention on the generics risk Novartis faces in its pharma business, Purcell tells investors in a research note. The analyst believes this generic pressure is not priced into shares of Novartis. His top pick remains Roche (RHHBY).
NVO Novo Nordisk
$50.21

-0.74 (-1.45%)

01/29/19
EXAN
01/29/19
INITIATION
EXAN
Outperform
Novo Nordisk reinstated with an Outperform at Exane BNP Paribas
04/11/19
GUGG
04/11/19
DOWNGRADE
GUGG
Neutral
Guggenheim sees limited upside for Eli Lilly, downgrades to Neutral
As previously reported, Guggenheim analyst Seamus Fernandez downgraded Eli Lilly (LLY) to Neutral from Buy, stating that while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. Though he still thinks Eli Lilly has "the best long-term growth profile in US Pharma," that growth is the broad consensus view, said Fernandez, who removed his price target on the stock but estimates the fair value to be in the range of $125-$135 per share.
01/23/19
OTRG
01/23/19
NO CHANGE
OTRG
Novo Nordisk Ozempic script growth accelerates, says OTR Global
OTR Global's checks indicate Novo Nordisk's Ozempic script growth accelerated during Q4.
02/01/19
MSCO
02/01/19
INITIATION
MSCO
Equal Weight
Novo Nordisk reinstated with an Equal Weight at Morgan Stanley
OSUR OraSure
$10.12

-0.12 (-1.17%)

01/04/19
ADAM
01/04/19
NO CHANGE
ADAM
Illumina, Exact Science among top Diagnostics picks for 2019 at Canaccord
Canaccord analyst Mark Massaro introduced his top picks for 2019 in the Diagnostics and Tools space as he expects new tests will generate clinical and economic utility to patients and payors, which will pace positive returns in 2019. His top picks include Illumina (ILMN) with a $375 price target, Exact Sciences (EXAS) with an $87 price target, Heska (HSKA) with a $123 target, Natera (NTRA) with a $25 target, OraSure (OSUR) with an $18 target and Quidel (QDEL) with a $70 price target.
07/17/18
ADAM
07/17/18
NO CHANGE
Target $20
ADAM
Buy
OraSure weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro said the weakness in OraSure following a competitor firm's downgrade is a buying opportunity. Massaro disagrees with the downgrade, as he believes the company's strategic review will serve as a catalyst and the Q2 results look achievable. He believes the selloff has provided a compelling opportunity to buy the shares. Massaro reiterated his Buy rating and $20 price target on OraSure, which fell about 6% yesterday to close at $16.28 per share.
10/23/18
RAJA
10/23/18
INITIATION
RAJA
Market Perform
OraSure resumed with a Market Perform at Raymond James
Raymond James analyst John Hsu resumed coverage on OraSure with a Market Perform saying there is limited visibility on HCV and would like to gain greater comfort with the strategic plan from the new management team before getting more positive on the shares.
11/08/18
ADAM
11/08/18
NO CHANGE
Target $18
ADAM
Buy
OraSure weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro said he would be a buyer of the weakness in OraSure following its Q3 results. He said the report was solid but the guidance may be disappointing to investors while he views it as being conservative. Massaro reiterated his Buy rating and lowered his price target to $18 from $20 on OraSure shares.
SIEGY Siemens
$0.00

(0.00%)

02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
JPMS
02/26/19
UPGRADE
JPMS
Overweight
Siemens upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Andreas Willi upgraded Siemens to Overweight and raised his price target for the shares to EUR 118 from EUR 115. The analyst sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." Siemens needs to adjust its Vision 2020+ strategy at the May meeting and reassure investors and provide substantiation of what will change, Willi tells investors in a research note.
01/15/19
RBCM
01/15/19
INITIATION
RBCM
Sector Perform
Siemens initiated with a Sector Perform at RBC Capital
08/16/18
BTIG
08/16/18
NO CHANGE
Target $72
BTIG
Buy
NuVasive price target raised to $72 from $68 at BTIG
BTIG analyst Ryan Zimmerman raised his price target on NuVasive (NUVA) to $72 and kept his Buy rating following investor meetings with the management, saying the tone of the discussions was "decidedly more upbeat" after Q2 results and the company's FY18 guidance cut. The analyst states that he also "underappreciated" the potential for NuVasive's recent agreement with Siemens (SIEGY), as it expands the company's opportunity and provides better commercial support. Zimmerman expects investor interest in NuVasive shares to build heading into the full launch of the company's new Pulse system.
JNJ Johnson & Johnson
$136.00

0.72 (0.53%)

04/09/19
NEED
04/09/19
UPGRADE
Target $3
NEED
Buy
Geron upgraded to Buy from Hold at Needham
Needham analyst Chad Messer upgraded Geron (GERN) to Buy with a price target of $3, saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity". The analyst cites the program's subsequent readouts from Phase II IMbark and IMerge studies in myelofibrosis and myelodysplastic syndrome, which he states has "established efficacy in both patient populations." Messer further contends that big pharma passing on imetelstat does not reflect a fundamental issue with the drug itself.
04/05/19
PIPR
04/05/19
NO CHANGE
Target $325
PIPR
Overweight
Piper a 'little cautious' on Q2 results for Cooper Companies
After speaking with a contact lens distributor, Piper Jaffray analyst Matt O'Brien is a "little cautious" on Cooper Companies' fiscal Q2 results. The shift to dailies continues, which is positive for the market as a whole, but Johnson & Johnson (JNJ) and Alcon were more aggressive in calendar Q1, so results for the category "may be a bit unusual," O'Brien tells investors in a research note. In addition to the "odd activity" from the two largest players, the analyst also heard about some "aggressive behavior" from Cooper in recent weeks, which makes him think the company should hit its numbers. He's still bullish on Cooper Companies capturing share in lenses in 2019 and 2020 and keeps an Overweight rating on the name.
04/08/19
PIPR
04/08/19
NO CHANGE
Target $20
PIPR
Overweight
Immunomedics deal with J&J indicates sacituzumab re-filing, says Piper Jaffray
Immunomedics (IMMU) this morning announced that it has entered into an agreement with Johnson & Johnson (JNJ) to provide detailing services to J&J for erdafitinib in the U.S. through Q1 of 2020, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes the deal will provide incremental revenue to Immunomedics while allowing the company to keep its sacituzumab-trained sales team on board while offsetting some of the costs. Further, the Q1 of 2020 termination suggests a potential timeline for a sacituzumab re-filing and approval, says Catanzaro, who notes Immunomedics has not yet provided guidance. The analyst remains comfortable with his mid-2020 approval timing for sacituzumab and keeps an Overweight rating on Immunomedics with a $20 price target.
04/09/19
PIPR
04/09/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALPINE data an incremental positive, says Piper Jaffray
After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is "not sure these data will be enough to move the needle." Brill maintains a Neutral rating on Alkermes.
SBPH Spring Bank Pharmaceuticals
$9.54

-0.29 (-2.95%)

08/14/18
PIPR
08/14/18
INITIATION
Target $25
PIPR
Overweight
Spring Bank Pharmaceuticals initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Spring Bank Pharmaceuticals with an Overweight rating and $25 price target. The company has reported "encouraging" proof-of-concept data from the first three cohorts of the Phase II study of monotherapy inarigivir, in development to treat hepatitis B virus infection, Tenthoff tells investors in a research note. The analyst sees inarigivir as the "essential" immunomodulatory component in combination therapy to achieve an HBV functional cure.
10/09/18
JEFF
10/09/18
INITIATION
Target $28
JEFF
Buy
Spring Bank Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Spring Bank Pharmaceuticals with a Buy rating and $28 price target. The company is developing inarigivir for hepatitis B virus and the drug is "de-risked" given its dose response and "excellent" safety profile, Raycroft tells investors in a research note. He believes inarigivir "could position as a backbone now and for the longer-term" in HBV treatment.
12/07/18
PIPR
12/07/18
NO CHANGE
Target $25
PIPR
Overweight
Spring Bank Pharmaceuticals R&D day highlights inarigivir, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff kept his Overweight rating and $25 price target on Spring Bank Pharmaceuticals after its R&D presentation yesterday. The analyst says the event highlighted the potency of inarigivir in Hepatitis B virus in patients as early as 12 weeks. Tenthoff further cites the final ACHIEVE data on the treatment likely coming at the EASL event in April of 2019, with additional studies taking place later next year.
08/03/18
JMPS
08/03/18
NO CHANGE
Target $20
JMPS
Outperform
Spring Bank's early inarigivir data 'promising,' says JMP Securities
After Spring Bank Pharmaceuticals reported data on the third cohort in the Phase 2 ACHIEVE trial of inarigivir in HBV patients that met the primary endpoints, safety and antiviral activity, at both week 12 and week 24, JMP Securities analyst Liisa Bayko called the early data "promising." She thinks inarigivir has the potential to be an "integral piece to many iterations of combinations," which could "put the company in play" if the evidence builds. Bayko reiterated her Outperform rating and $20 price target on Spring Bank shares.

TODAY'S FREE FLY STORIES

ADTN

Adtran

$17.39

-0.38 (-2.14%)

13:40
04/25/19
04/25
13:40
04/25/19
13:40
Earnings
Adtran VP Roger Shannon sold over $100K in company shares »

Adtran VP Roger Shannon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

AVYA

Avaya

$20.22

0.895 (4.63%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Periodicals
Mitel offering to combine with Avaya in stock deal worth over $2B, WSJ says »

Avaya is in talks to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TECK.B

Teck Corp.

$0.00

(0.00%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Conference/Events
Teck Corp. management to meet with B.Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

CWT

California Water Service

$49.43

-0.57 (-1.14%)

13:32
04/25/19
04/25
13:32
04/25/19
13:32
Upgrade
California Water Service rating change  »

California Water Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHC

Bausch Health

$23.18

0.16 (0.70%)

13:30
04/25/19
04/25
13:30
04/25/19
13:30
Hot Stocks
Breaking Hot Stocks news story on Bausch Health »

Bausch Health trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

AVYA

Avaya

$20.20

0.875 (4.53%)

13:28
04/25/19
04/25
13:28
04/25/19
13:28
Periodicals
Mitel offers to combine with Avaya in stock deal, WSJ says »

Mitel's bid values…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

CLVS

Clovis

$19.43

-0.4 (-2.02%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 31

    May

AGN

Allergan

$140.66

0.98 (0.70%)

, TEVA

Teva

$15.07

0.065 (0.43%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Conference/Events
Piper Jaffray specialty pharma analysts to hold analyst/industry conference call »

Specialty Pharmaceuticals…

AGN

Allergan

$140.66

0.98 (0.70%)

TEVA

Teva

$15.07

0.065 (0.43%)

ALDR

Alder Biopharmaceuticals

$13.95

0.29 (2.12%)

AMGN

Amgen

$179.82

1.56 (0.88%)

BHVN

Biohaven Pharmaceutical

$62.30

-0.855 (-1.35%)

LLY

Eli Lilly

$117.99

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 21

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

ZM

Zoom Video

$64.49

1.175 (1.86%)

13:21
04/25/19
04/25
13:21
04/25/19
13:21
Hot Stocks
Zoom, Slack announce new partnership »

Zoom and Slack have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$23.18

0.16 (0.70%)

13:21
04/25/19
04/25
13:21
04/25/19
13:21
Hot Stocks
Bausch Health announces FDA approval of Duobrii for plaque psoriasis »

Bausch Health and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
04/25/19
04/25
13:17
04/25/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
04/25/19
04/25
13:16
04/25/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$382.62

7.3 (1.95%)

13:16
04/25/19
04/25
13:16
04/25/19
13:16
Recommendations
Boeing analyst commentary at Bernstein »

Bernstein says Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    May

  • 05

    Jun

BA

Boeing

$382.62

7.3 (1.95%)

13:15
04/25/19
04/25
13:15
04/25/19
13:15
Periodicals
FAA targeting May 23 for meeting over 737 MAX changes, Aviation Week says »

The FAA is targeting May…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    May

  • 05

    Jun

13:12
04/25/19
04/25
13:12
04/25/19
13:12
General news
7-Yr Note Auction Coupon Rate data reported »

7-Yr Note Auction Coupon…

13:12
04/25/19
04/25
13:12
04/25/19
13:12
General news
7-Yr Note Auction Total Amount data reported »

7-Yr Note Auction Total…

RSG

Republic Services

$79.29

-0.01 (-0.01%)

13:10
04/25/19
04/25
13:10
04/25/19
13:10
Options
Upside call buys in Republic Services ahead of earnings »

Upside call buys in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    May

  • 17

    May

  • 05

    Jun

LUV

Southwest

$54.00

1.08 (2.04%)

13:06
04/25/19
04/25
13:06
04/25/19
13:06
Hot Stocks
Breaking Hot Stocks news story on Southwest »

Southwest continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

LUV

Southwest

$54.00

1.08 (2.04%)

, BA

Boeing

$379.25

3.93 (1.05%)

13:06
04/25/19
04/25
13:06
04/25/19
13:06
Hot Stocks
Southwest expects FY19 capacity to increase 2%-3% y-o-y »

Says continues to have…

LUV

Southwest

$54.00

1.08 (2.04%)

BA

Boeing

$379.25

3.93 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

  • 15

    May

  • 21

    May

  • 29

    May

  • 05

    Jun

  • 13

    Nov

BUD

AB InBev

$86.38

-1.82 (-2.06%)

13:05
04/25/19
04/25
13:05
04/25/19
13:05
Options
Anheuser Busch call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

13:05
04/25/19
04/25
13:05
04/25/19
13:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

APD

Air Products

$199.33

-0.17 (-0.09%)

, PKX

Posco

$55.45

-0.75 (-1.33%)

13:02
04/25/19
04/25
13:02
04/25/19
13:02
Hot Stocks
Air Products to supply Posco's cathode material manufacturing site in Gwangyang »

Air Products (APD)…

APD

Air Products

$199.33

-0.17 (-0.09%)

PKX

Posco

$55.45

-0.75 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$54.18

1.26 (2.38%)

13:02
04/25/19
04/25
13:02
04/25/19
13:02
Hot Stocks
Southwest expects Q2 economic fuel costs $2.10-$2.20 per gallon »

Says continues to expect…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

13:00
04/25/19
04/25
13:00
04/25/19
13:00
General news
Treasury $32 B 7-year auction preview: »

Treasury $32 B 7-year…

BDRBF

Bombardier

$0.00

(0.00%)

12:59
04/25/19
04/25
12:59
04/25/19
12:59
Downgrade
Bombardier rating change at Scotiabank »

Bombardier downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.